Fiona Carlon, Author at Rimon Law

Nasdaq’s New $25 Million Listing Standard for China-Based Companies: What Executives Need to Know

InsightsBy Fiona Carlon May 22, 2026

Effective Date: Anticipated Mid-June 2026 On May 14, 2026, the U.S. Securities and Exchange Commission (the “SEC”) approved a significant change to Nasdaq’s listing standards that will affect how certain China-based companies access Nasdaq’s U.S. public equity markets. Under new Nasdaq Rule 5210(l), China-based companies—including those headquartered or incorporated in mainland China, Hong Kong, or…

Rimon Law Adds 10 Attorneys in Q1 2026, Deepening Bench in Litigation, Government Contracts, Private Client, and Capital Markets

NewsBy Fiona Carlon May 20, 2026

NEW YORK — May, 20 2026 — Rimon Law, a full service global law firm, added 10 attorneys in the first quarter of 2026, expanding into new geographies and strengthening key practice areas as the firm continues a period of sustained growth. The quarter included the opening of Rimon’s new Nashville office, the firm’s first…

Rimon Law Earns NAMWOLF Certification, Becomes the Largest Firm in the Organization’s Membership

Diversity, NewsBy Fiona Carlon May 14, 2026

Rimon Law, a full-service global law firm, has been certified as a member of the National Association of Minority and Women Owned Law Firms (NAMWOLF). With more than 200 attorneys throughout the U.S. and globally, Rimon is now the largest law firm in the organization’s membership. NAMWOLF is a nonprofit trade association founded in 2001…

Rimon Client ARC Group Acquisition I Corp Announces Closing of Initial Public Offering and Listing on NASDAQ

NewsBy Fiona Carlon May 4, 2026

Rimon client, ARC Group Acquisition I Corp (the “Company”) announced on May 1 that it closed its initial public offering, selling 12,075,000 units at $10.00 each, including 1,575,000 units issued pursuant to the exercise of the underwriters’ over-allotment option in full, for total gross proceeds of $120,750,000. Units began trading on the Nasdaq Global Market…

Rimon Client, CADV Ventures S.A. Enters into Business Combination with Miluna Acquisition Corp

NewsBy Fiona Carlon April 30, 2026

Rimon client, CADV Ventures S.A., an AI software company focused on improving digital customer engagement for large organizations (“CADV.AI”), and Miluna Acquisition Corp (NASDAQ: MMTX) (“Miluna”), a special purpose acquisition company, have announced that they have entered into a definitive business combination agreement. Upon closing of the proposed business combination, the combined company will operate…

Rimon Helps Chinese Companies Beat Jurisdiction Claims and End Litigation

NewsBy Fiona Carlon October 28, 2025

We congratulate our client on their recent victory in litigation involving a disgruntled former employee and complex cross border issues. Congratulations to our team, Zheng Liu, Scott Raber, Bob Cocchia and Kendra Orr who represented the Chinese companies. A summary of the case, along with some practical suggestions for foreign companies on what to do…

Rimon Team at 2025 International Bar Association Conference in Toronto

NewsBy Fiona Carlon October 15, 2025

Rimon is pleased to share that we have a team of attorneys attending the International Bar Association Conference on November 2-7 at the Metro Toronto Convention Centre, Toronto. In addition, Rimon Partner and member of the IBA Asset Recovery Committee, Neal Levin will be speaking at the IBA session, “Can you trust a trust? Treatment…

Dogwood Therapeutics Secures License from Serpin Pharma to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction

NewsBy Fiona Carlon October 9, 2025

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and neuropathy, recently announced that in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) formulation of SP16 to manage cancer related pain (CRP) including a broad range…

September 2025 Trade & Tariff Update: Key Insights from Sandra Bell

InsightsBy Fiona Carlon September 30, 2025

Rimon partner Sandra Bell shared critical updates in September on the shifting landscape of international tariffs, including major judicial developments and new guidance issued by U.S. Customs and Border Protection (CBP) under the International Emergency Economic Powers Act (IEEPA). CAFC Upholds CIT Decision on IEEPA Tariffs Sandra noted that the Court of Appeals for the…

August 2025 Trade & Tariff Update: Key Insights from Sandra Bell

InsightsBy Fiona Carlon August 31, 2025

Rimon partner Sandra Bell shared several important updates in August related to new Executive Orders and U.S. Customs and Border Protection (CBP) guidance under the International Emergency Economic Powers Act (IEEPA), as the reciprocal tariff program continues to evolve. CBP Issues Guidance on IEEPA Tariff Updates Effective August 7 Sandra highlighted new U.S. Customs and Border…

Search our capabilities across practice areas, industries and regions

Search the Rimon Team

Offices

Regional Practices

Nasdaq’s New $25 Million Listing Standard for China-Based Companies: What Executives Need to Know

Rimon Law Adds 10 Attorneys in Q1 2026, Deepening Bench in Litigation, Government Contracts, Private Client, and Capital Markets

Rimon Law Earns NAMWOLF Certification, Becomes the Largest Firm in the Organization’s Membership

Rimon Client ARC Group Acquisition I Corp Announces Closing of Initial Public Offering and Listing on NASDAQ

Rimon Client, CADV Ventures S.A. Enters into Business Combination with Miluna Acquisition Corp

Rimon Helps Chinese Companies Beat Jurisdiction Claims and End Litigation

Rimon Team at 2025 International Bar Association Conference in Toronto

Dogwood Therapeutics Secures License from Serpin Pharma to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction

September 2025 Trade & Tariff Update: Key Insights from Sandra Bell

August 2025 Trade & Tariff Update: Key Insights from Sandra Bell